{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:26:57Z","timestamp":1767979617050,"version":"3.49.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00508-021-01850-x","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T13:02:41Z","timestamp":1617973361000},"page":"80-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psoas muscle index at the time of diagnosis might reflect the prognosis of classical Hodgkin\u02bcs lymphoma patients"],"prefix":"10.1007","volume":"134","author":[{"given":"Marko","family":"Lucijani\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Huzjan Koruni\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Ivi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina","family":"Fazli\u0107 D\u017eanki\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017deljko","family":"Jonji\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdravko","family":"Mitrovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017deljko","family":"Prka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Pir\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozren","family":"Jak\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petar","family":"Ga\u0107ina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josipa","family":"Vlasac Glasnovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlatko","family":"Pej\u0161a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"issue":"1","key":"1850_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","volume":"6","author":"JM Connors","year":"2020","unstructured":"Connors\u00a0JM, Cozen\u00a0W, Steidl\u00a0C, et\u00a0al. Hodgkin lymphoma. Nat Rev Dis Primers. 2020;6(1):61.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1850_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/17474086.2020.1746183","volume":"13","author":"M Cirillo","year":"2020","unstructured":"Cirillo\u00a0M, Borchmann\u00a0S. An update on disease biomarkers for Hodgkin lymphoma. Expert Rev Hematol. 2020;13(5):481\u20138.","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"1850_CR3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","volume":"16","author":"M Hutchings","year":"2005","unstructured":"Hutchings\u00a0M, Mikhaeel\u00a0NG, Fields\u00a0PA, Nunan\u00a0T, Timothy\u00a0AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160\u20138.","journal-title":"Ann Oncol"},{"key":"1850_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1856833.","author":"U Iltar","year":"2020","unstructured":"Iltar\u00a0U, S\u00f6zel\u00a0H, S\u00f6zel\u00a0YK, et al. Prognostic impact of the psoas muscle index, a\u00a0parameter of sarcopenia, in patients with diffuse large B\u2011cell lymphoma treated with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2020; https:\/\/doi.org\/10.1080\/10428194.2020.1856833.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1850_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00277-020-04243-8","volume":"100","author":"M Lucijanic","year":"2021","unstructured":"Lucijanic M, Galusic D, Soric E, et\u00a0al. Ruxolitinib treatment improves muscle mass in patients with myelofibrosis. Ann Hematol. 2021;100(4):1105-1106.","journal-title":"Ann Hematol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01850-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-021-01850-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01850-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T11:24:04Z","timestamp":1643887444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-021-01850-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":5,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1850"],"URL":"https:\/\/doi.org\/10.1007\/s00508-021-01850-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"6 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"M.\u00a0Lucijani\u0107, R.\u00a0Huzjan Koruni\u0107, M.\u00a0Ivi\u0107, A.\u00a0Fazli\u0107 D\u017eanki\u0107, \u017d.\u00a0Jonji\u0107, Z.\u00a0Mitrovi\u0107, \u017d.\u00a0Prka, M.\u00a0Pir\u0161i\u0107, O.\u00a0Jak\u0161i\u0107, P.\u00a0Ga\u0107ina, J.\u00a0Vlasac Glasnovi\u0107 and V.\u00a0Pej\u0161a declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}